Did you know Immunocal has a patent application for compositions and methods to aid Autism Spectrum Disorder? A huge accomplishment in Autism research and a promising development for individuals and families affected by this neurodevelopmental disorder.
Patent application number: 16/634,946
Unpacking the Study: Immunocal’s Impact on ASD
Autism spectrum disorder affects as many as 1 in 54 children in the Unites States alone, and the numbers are rising. Conventional medical treatments have had limited impact on improving the condition, which has led to the exploration of new therapies and treatments. Recent research has found that many autistic individuals have increased markers of oxidative stress and mitochondrial dysfunction, lowered glutathione levels, as well as genetic abnormalities in the glutathione pathway. This has led to the hypothesis that a nutritional supplement based on cysteine-rich whey proteins serving as glutathione precursors can improve behavioral function in children with autism.
Nova Southeastern University in Florida, conducted a study that evaluated the effects of our unique cysteine-rich whey protein isolate formulation (Immunocal®) on pre-school children with autism, and the results were nothing short of groundbreaking.
The study enrolled 60 subjects, with 20 randomly assigned to treatment with Immunocal for three months, and 20 assigned to a control group receiving rice protein. Core areas of autistic behavior were assessed before and after treatment, including atypical behaviors, communication, developmental status, and behavioral problems. Blood glutathione levels were also quantified before and after treatment.
The results showed that children receiving Immunocal demonstrated significant improvements in their behavioral function compared to the control group. Blood glutathione levels were also found to be increased in the Immunocal group.
💙 April is Autism Acceptance Month!
“Improving the quality of life for children with Autism was a bonus. 💙🤝 This April, let’s work together to create a more understanding and helpful world for individuals with autism. Together, we can break down barriers and promote inclusion.” Immunotec CEO, Mauricio Domenzain
“As we observe this month, it is important to continue exploring new treatments and therapies for individuals with autism and support ongoing research in this area. Help spread the word and show your support. With continued research and exploration of new treatments and therapies, we can help to make a difference in the lives of families everywhere.” Dr. Jimmy Gutman SAB Chairman and World’s Leading Authority on Glutathione
Join us in supporting #AutismAcceptanceMonth and the important research that was conducted at NSU on the effects of Immunocal on children with ASD. Together, we can make a difference 💙🤝🧩 #Immunotec #NSU #ASD #Research#LightItUpBlue #ThankYouImmunocal
+ Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/study/NCT01366859 identifier: NCT01366859
+ PMCID: PMC8514994
+ United States Patent Application No. 16/634,946 Filed July 31, 2018 “COMPOSITIONS AND METHODS FOR TREATMENT OF AUTISM SPECTRUM DISORDER”
*These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease. Immunotec does not guarantee that anyone will make a specific amount of money. This post is intended for the US market.